[3][4] Guineensine inhibits the cellular reuptake of anandamide and 2-arachidonoylglycerol in a mouse model (EC50 = 290 nM).

[5] [6] This causes an increase in the activity of the two neurotransmitters which are classified as endogenous cannabinoids.

Guineesine can dose-dependently produce cannabimimetic effects in a mouse model[5] which are indicated by potent catatonic, analgesic, hypo-locomotive and hypo-thermic effects.

In addition, the analgesic and catatonic effects were reversed by the cannabinoid receptor type 1 (CB1) inverse agonist rimonabant.

[5] Guineesine is also a monoamine oxidase inhibitor (MAOI) in vitro (IC50 = 139.2 μM).